[Development of resistance in Fisher lymphadenosis cells to dipin and bruneomycin when these preparations are used separately and in combination].
It was shown that dipin and bruneomycin resistant tumor cells appeared in mice with transplanted lymphadenosis after 10 passages on single use of the drugs. When the drugs were used in combination, no lymphadenosis cells resistant either to bruneomycin, or to dipin and their combination were found. The combined use of the drugs prevented development of resistance to them in the lymphadenosis cells at least during 10 passages on mice. The data on the possible prevention of the resistance development in the mouse lymphadenosis cells by means of combined use of low doses of dipin and bruneomycin provided an assumption that it is expedient to test the combination in clinics.
D000477:Alkylating Agents / Q000494:pharmacology*; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002460:Cell Line; D002471:Cell Transformation, Neoplastic / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D004351:Drug Resistance; D008223:Lymphoma / Q000188:drug therapy*; D051379:Mice; D009368:Neoplasm Transplantation; D010879:Piperazines / Q000494:pharmacology; D013308:Streptonigrin / Q000494:pharmacology*
D000477:Alkylating Agents; D000970:Antineoplastic Agents; D004338:Drug Combinations; D010879:Piperazines; D013308:Streptonigrin
Razvitie ustoĭchivosti u kletok limfadenoza Fishera k dipinu i bruneomitsinu pri razdel'nom i sochetannom primenenii étikh preparatom